OBJECTIVE： To study the effects of nimesulide combined with oxaliplatin on transplanted tumor growth and immune function of rats with esophageal cancer. METHODS： Rats were randomly divided into model group （intragastrically given Sodium carboxymethyl cellulose solution+intravenously given 5％ Glucose injection in tail）， nimesulide group （intragastrically given 20 mg/kg）， oxaliplatin group （intravenously given 13.6 mg/kg in tail） and combination group， 10 in each group. Esophageal cancer Eca109 cells were subcutaneously injected to develop transplanted tumor model. After modeling， rats in each group received relevant medicines by corresponding ways， once a day for ig， once every 4 d for iv in tail. Rats were sacrificed after 8 weeks， tumor volume and quality of rats were measured， tumor inhibition rate was calculated， and contents of tumor markers （CEA， CYFRA21- 1， SCCAg）， percentages of immune cells （CD3+， CD4+， CD8+ T cells and NK cell） in peripheral blood were detected. RESULTS： Compared with model group， tumor volume and quality in other 3 groups were decreased （P＜0.05）； contents of tumor markers were decreased （P＜0.05）. Percentages of CD3+， CD4+ T cells and NK cell in nimesulide group were increased， percentages of CD8+ T cell was decreased （P＜0.05）. Percentages of CD3+， CD4+ T cells and NK cell in oxaliplatin group and combination group were decreased， percentages of CD8+ T cell was increased （P＜0.05）. Compared with nimesulide group and oxaliplatin group， tumor inhibition rate in combination group was increased （P＜0.05）； contents of tumor markers were decreased （P＜0.05）； percentages of immune cells were lower than nimesulide group and higher than oxaliplatin group （P＜0.05）. CONCLUSIONS： Nimesulide can enhance the oxaliplatin’s antitumor effect on esophageal cancer， and decrease its inhibition degree on immune functions.